VEGFA and ovarian carcinoma: Bevacizumab is a humanized monoclonal antibody that recognizes circulating vascular endothelial growth factor (VEGF) and which has documented anti-cancer activity patients with recurrent ovarian cancer [30], [31], [32], [33], [34], [35].